Trial results

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

NCT06738979 on ClinicalTrials.gov · last registry update 2024-12-18

Registered but never opened — and the completion date on file, July 2026, has already passed. Its estimated completion date, July 2026, has passed with no update to the record. Primary outcome, as filed: Percentage (%) of body weight loss. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sponsor type

Industry

Enrollment

408

Started

2025-03

Primary completion

2026-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage (%) of body weight loss

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.